Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen’s Phase II Lupus Success Offers An Additional Viable Pipeline Asset

Executive Summary

While Biogen is seeking to diversify its R&D efforts, unexpected good data in two forms of lupus make internally discovered BIIB059 a viable asset to take forward, although Phase III plans are not set.

You may also be interested in...



Aurinia Closing In On Lupus Nephritis With Voclosporin

Canada’s Aurinia Pharmaceuticals expects to file a US NDA in the first half of next year on the use of its next-generation calcineurin inhibitor, voclosporin, in lupus nephritis, a condition with no approved therapies.


AstraZeneca Closer To Filing Anifrolumab For Lupus

Having recovered from a late-stage fail last year, AstraZeneca has fleshed out results from a positive second Phase III trial of anifrolumab which it hopes will be the second new lupus treatment to hit the market in 60 years.

IPF Failure Sets Back Biogen’s Diversification Efforts

The company has discontinued a Phase II trial for BG00011, which was acquired in its 2012 Stromedix purchase, due to safety issues.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141282

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel